Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice. (October 2018)

• Record Type: Journal Article
• Authors: Vohnout, Branislav; Fábryová, Ľubomíra; Klabník, Alexander; Kadurová, Michaela; Bálinth, Karin; Kozárová, Miriam; Bugáňová, Ingrid; Sirotiaková, Jana; Rašlová, Katarína
• Is Part Of: Atherosclerosis. Volume 277(2018)
• Page Start: 323
• Page End: 326
• Publication Date: 2018-10
• Subjects: Familial hypercholesterolemia -- Statins -- LDL-C -- Goal levels; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2018.06.857
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Background and aims: Maximal doses of potent statins are the cornerstone of treatment of familial hypercholesterolemia (FH). Despite this, a substantial proportion of FH patients are either under-treated or not treated at all. The aim of this work was to evaluate, in a retrospective study, the treatment of FH patients, the proportion of FH patients reaching low-density lipoprotein cholesterol (LDL-C) goals, and reasons for not reaching LDL-C goals, in 8 lipid clinics in Slovakia dealing with FH patients. Methods: 201 heterozygous FH patients (50.8 ± 14.9 years, 55% females) who attended the lipid clinics at least three times were included in the study. Results: At the first visit, 31.3% of patients were treated with statins and the most common dose was 20 mg of atorvastatin, rosuvastatin and simvastatin. At the third visit, 78.1% of patients were treated with statins and 24.4% with ezetimibe. The majority of patients were treated with atorvastatin (75.8%) and rosuvastatin (18.5%) and 31.3% of all patients were treated with atorvastatin 80 mg or rosuvastatin 40 mg with/without ezetimibe. However, only 11.9% of patients with the LDL-C goal level <2.5 mmol/l and 6.9% with the goal <1.8 mmol/l reached the level. Reasons for not reaching the goal levels were evaluated by physicians in each patient. Insufficient LDL-C lowering effect of treatment, side-effects of therapy and non-compliance of patients were responsible for 46%, 18% and 30% of cases, respectively. Conclusions: Referral of FH patients to lipid clinics in Slovakia leads to improvement in the treatment; however, almost 22% of the patients are still without statin treatment and the majority of patients do not reach the LDL-C goal level. Highlights: A substantial proportion of FH patients are undertreated in Slovakia. Reference of FH patients to specialised clinics leads to improvement in the treatment. The majority of FH patients do not reach LDL-C goal levels despite specialised management.